UPM New Commercial Manufacturing Facility

UPM Pharmaceuticals, a Baltimore, Maryland-based drug development and contract manufacturer, announced today that they will be acquiring the 500,000 square-foot commercial manufacturing facility that Pfizer Inc. (PFE) currently operates in Bristol, TN. The acquisition of the Pfizer facility will provide UPM with large scale commercial capabilities for manufacturing and packaging of solid oral dosage tablets and capsules, as well as semi-solid manufacturing of creams and ointments. The facility will also provide for comprehensive tech transfer support, pilot plant scale-up capabilities, analytical and microbial testing, as well as dedicated suites for potent compounds. As part of the purchase, UPM will continue to manufacture Pfizer’s current portfolio of products within the facility for two years. The acquisition will allow UPM Pharmaceuticals to offer a full range of development, testing and manufacturing capabilities to its existing and new clients.